Skip to Content
Search Menu

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

The CAPTIVATE study’s latest findings offer new hope for CLL/SLL patients with the oral ibrutinib-venetoclax, demonstrating lasting remissions and promising retreatment outcomes.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video 02:15
Paolo Ghia

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Paolo Ghia
ASH24CLL Play the Video 03:54
Jennifer R Brown

Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

/ Jennifer R. Brown
ASH24CLL Play the Video 04:11
Florian Simon

Acalabrutinib Shows Promise for Elderly CLL Patients

/ Florian Simon
ASH24CLL Play the Video 05:20

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
CLLEHA24
Paolo Ghia

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

/ Paolo Ghia
CLLEHA24 Play the Video 02:42
Alessandra Tedeschi

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

/ Alessandra Tedeschi
CLLEHA24 Play the Video 01:52

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jason Westin

Potential for Targeted and Immune-Facing Therapies for Patients with CNS Lymphoma

/ Jason Westin
ASH23Lymphoma Play the Video 01:08
Back to top